"This is an historic moment for NutraCea(R)" - 500 Beiträge pro Seite

[V51]

(PR NEWSWIRE) NutraCea`s SynBiotics-3 Formula Approved by Mercy Hospital of Fol
om Formulary Committee as Adjunctive Therapy in the M
NutraCea`s SynBiotics-3 Formula Approved by Mercy Hospital of Folsom Formulary C
mmittee as Adjunctive Therapy in the Management of Recurrent Clostridia Difficil
Colitis

EL DORADO HILLS, Calif., Sept. 21 /PRNewswire-FirstCall/ -- NutraCea
(OTC Bulletin Board: NTRZ) announced today that their SynBiotics-3, a
proprietary formulation of pre and probiotics, has been approved to be added
to the formulary at Mercy Hospital of Folsom as adjunctive therapy in the
management of recurrent Clostridia difficile colitis, more commonly known as
antibiotic-associated diarrhea.
SynBiotics-3 contains bacteria called Saccharomyces, which have been shown
in independent clinical trials to reduce the recurrence rate of C. difficile
colitis. In addition, SynBiotics-3 contains NutraCea`s proprietary
fructo-oligosaccharide-rich stabilized rice bran derivative "RiSolubles(R)" as
well as other "friendly" bacterial strains. Fructo-oligosaccharides (FOS), as
prebiotics, have been shown to help support and maintain healthy intestinal
flora.
Dr. Eliot Drell and Dr. Erick Pecha are board certified
gastroenterologists who co-developed the product with Patricia McPeak, Founder
of NutraCea. Dr. Drell stated, "We are very gratified that Mercy Hospital of
Folsom has agreed to add SynBiotics-3 to their armamentarium for the
management of a very challenging and common problem that often accompanies the
use of broad-spectrum antibiotic therapy."
Mercy Hospital of Folsom is part of Catholic Hospitals West, a large
organization of Hospitals under the Mercy name, with locations throughout
California. The approval is hoped to lead to adoption into formularies
throughout this organization as well as other hospitals throughout the
country. This will help pave the way for physicians in a hospital setting to
begin to prescribe SynBiotics-3 to assist in the management of this condition.
SynBiotics-3 has been restricted for use in only those patients who are not
immuno-compromised and who can take oral medications.
"This is an historic moment for NutraCea(R) and CHW`s Mercy Hospital of
Folsom and constitutes a significant milestone in the implementation of a
truly integrative healthcare system, which will allow physicians the
opportunity to prescribe natural and effective therapies alongside more
conventional treatment modalities for the betterment of their patients.
In-patients will now have the same opportunity to benefit from the same
probiotics that physicians are recommending to their out-patients," said
Patricia McPeak, Founder and CEO of NutraCea.
About Clostridia difficile colitis
C. difficile colitis can be a serious problem and is most commonly seen as
a complication from the use of broad-spectrum antibiotics. These widely used
medications suppress a patient`s normal, healthy intestinal flora allowing the
C. difficile organism to proliferate. The most common treatment has been the
use of other, different antibiotics to eradicate the organism, however, there
is always an underlying recurrence rate following standard treatment and
recently some resistant species have begun to emerge, hampering physicians`
usual treatment protocols. Although antibiotic-induced diarrhea can be as mild
as a self-limited diarrheal disorder, in older debilitated patients, the
condition can sometimes be serious requiring hospitalization and intensive
treatment. Though rare, the disease can be fatal.
About NutraCea
NutraCea is a leader in stabilized rice bran nutrient research and dietary
supplement development. The Company has developed intellectual property to
create a range of proprietary product formulations, delivery systems and whole
food nutrition products. NutraCea`s proprietary technology enables the
creation of food and nutrition products from rice bran, normally a waste by-
product of standard rice processing. In addition to its whole foods products,
NutraCea develops families of health-promoting "nutraceuticals," including
natural arthritic relief and cholesterol-lowering products, and all-natural
"cosmeceutical" beauty aids. More information can be found in the company`s
filings with the SEC and you can visit the NutraCea web site
http://www.NutraCea.com.
Forward Looking Statements
This release contains forward-looking statements, including statements
regarding anticipated revenue. Actual results may differ from those projected
due to a number of risks and uncertainties, including, but not limited to,
agreement on the terms of the contemplated agreement with the Dominican
Republic government, successful completion of the production facility, product
demand and market acceptance, the impact of the competitive products and
pricing, new product development, reliance on key strategic alliances,
availability of materials, the regulatory environment, and other risks
detailed from time to time in the company`s filings with the Securities and
Exchange Commission. The Company does not undertake to update forward-
looking statements in this news release to reflect actual results, changes in
assumptions or changes in other factors affecting such forward-looking
information. Assumptions and other information that could cause results to
differ from those set forth in the forward-looking information can be found in
the Company`s filings with the Securities and Exchange Commission, including
the company`s most recent periodic report.
Company Contact:
Margie Adelman
Senior V.P. NutraCea
916-933-7000 Ext. 646
916-220-3500 cell

Investor Relations Contact:
Stephen D. Axelrod, CFA
Wolfe Axelrod Weinberger Associates, LLC
212-370-4500
SOURCE NutraCea


Contact Information:
Margie Adelman, Senior V.P., NutraCea, [phone] Ext. 646, [phone]
cell; Investor Relations: Stephen D. Axelrod, CFA, Wolfe Axelrod Weinberger Asso
iates, LLC, [phone]

WebSite:
http://www.NutraCea.com
*** end of story ***

[Loserin]

Kannst Du bitte noch 5 Threads aufmachen
Für die User die deutsch, französich, polnisch, türkisch,
spanisch denken